Search

Author/Creator Lawitz, Eric

1. 820Triple Combination Treatment With Peginterferon Lambda-1a, Daclatasvir and Ribavirin for 12 Weeks in Patients Infected With HCV Genotype 1b. (December 2014)

Authors:
Brunetto, Maurizia; Rana, Khurram; Taliani, Gloria; Lawitz, Eric; Hézode, Christophe; Marcellin, Patrick; Serfaty, Lawrence; Cohen, David; Srinivasan, Subasree
Journal:
Open forum infectious diseases
Issue:
Volume 1(2014)Supplement 1
Page Start:
S233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease. Issue 10 (November 2020)

Authors:
Singh, Amandeep; Gosai, Falgun; Siddiqui, Mohamed T.; Gupta, Mohit; Lopez, Rocio; Lawitz, Eric; Poordad, Fred; Carey, William; McCullough, Arthur; Alkhouri, Naim
Journal:
Journal of clinical gastroenterology
Issue:
Volume 54:Issue 10(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials. (18th October 2019)

Authors:
Brown, Ashley; Welzel, Tania M.; Conway, Brian; Negro, Francesco; Bräu, Norbert; Grebely, Jason; Puoti, Massimo; Aghemo, Alessio; Kleine, Henning; Pugatch, David; Mensa, Federico J.; Chen, Yaozhu J.; Lei, Yang; Lawitz, Eric; Asselah, Tarik
Journal:
Liver international
Issue:
Volume 40:Number 4(2020)
Page Start:
778
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study. Issue 4 (10th March 2015)

Authors:
Nelson, David R.; Cooper, James N.; Lalezari, Jacob P.; Lawitz, Eric; Pockros, Paul J.; Gitlin, Norman; Freilich, Bradley F.; Younes, Ziad H.; Harlan, William; Ghalib, Reem; Oguchi, Godson; Thuluvath, Paul J.; Ortiz‐Lasanta, Grisell; Rabinovitz, Mordechai; Bernstein, David; Bennett, Michael; Hawk...
Journal:
Hepatology
Issue:
Volume 61:Issue 4(2015:Apr.)
Page Start:
1127
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. All‐oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment‐naïve patients with genotype 1 HCV infection. Issue 1 (28th May 2014)

Authors:
Wyles, David L.; Rodriguez‐Torres, Maribel; Lawitz, Eric; Shiffman, Mitchell L.; Pol, Stanislas; Herring, Robert W.; Massetto, Benedetta; Kanwar, Bittoo; Trenkle, James D.; Pang, Phil S.; Zhu, Yanni; Mo, Hongmei; Brainard, Diana M.; Subramanian, G. Mani; McHutchison, John G.; Habersetzer, Françoi...
Journal:
Hepatology
Issue:
Volume 60:Issue 1(2014:Jul.)
Page Start:
56
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Issue 4 (3rd February 2017)

Authors:
Poordad, Fred; Lawitz, Eric; Gutierrez, Julio A.; Guerrero, Juan; Speeg, Kermit; Swenson, Eugene S.
Journal:
Clinical case reports
Issue:
Volume 5:Issue 4(2017)
Page Start:
371
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Issue 4 (May 2018)

Authors:
Lawitz, Eric; Yang, Jenny C; Stamm, Luisa M; Taylor, James G; Cheng, Guofeng; Brainard, Diana M; Miller, Michael D; Mo, Hongmei; Dvory-Sobol, Hadas
Journal:
Antiviral therapy
Issue:
Volume 23:Issue 4(2018)
Page Start:
325
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus. Issue 1 (24th November 2014)

Authors:
Yoshida, Eric M.; Sulkowski, Mark S.; Gane, Edward J.; Herring, Robert W.; Ratziu, Vlad; Ding, Xiao; Wang, Jing; Chuang, Shu‐Min; Ma, Julie; McNally, John; Stamm, Luisa M.; Brainard, Diana M.; Symonds, William T.; McHutchison, John G.; Beavers, Kimberly L.; Jacobson, Ira M.; Reddy, K. Rajender; L...
Journal:
Hepatology
Issue:
Volume 61:Issue 1(2015:Jan.)
Page Start:
41
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗